Maintenance Notice (10:30 PM January 4 - 8:00 AM January 5, 2025 UTC): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.197 | Notice of Discontinuing the Use of Password-Protected Compressed Files | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
请选择数量
CAS RN: 42017-89-0 | 產品號碼: F1011
產品規格
Appearance | White to Almost white powder to crystal |
Purity(GC) | min. 98.0 % |
Purity(Neutralization titration) | min. 98.0 % |
Melting point | 179.0 to 183.0 °C |
性質
熔點 | 181 °C |
GHS
圖形表示 | |
信號詞 | Warning |
危險性說明 | H302 : Harmful if swallowed. H411 : Toxic to aquatic life with long lasting effects. |
防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P273 : Avoid release to the environment. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P391 : Collect spillage. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
相關法規
RTECS # | UA2453000 |
運輸資料
UN編號 | UN3077 |
類別 | 9 |
包裝類別 | III |
HS編碼* | 2918.30-000 |
Application
Fenofibric Acid: An Activator of peroxisome proliferator activated receptor α(PPARα)
Fenofibric acid, an active form of fenofibrate [F0674], activates peroxisome proliferator activated receptor α (PPARα) to modify fatty acid and lipid metabolite. Therefore, fenofibric acid helps reduce lowering triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C) levels, and increase low-density lipoprotein cholesterol (LDL-C) level in the blood. Fenofibric acid and fenofibrate are often co-administered with a HMG-CoA reductase inhibitor (statin) to the treatment of dyslipidemia. (The product is for research purpose only.)
References
- Fenofibric Acid, an Active Form of Fenofibrate, Increases Apolipoprotein A-I-Mediated High-Density Lipoprotein Biogenesis by Enhancing Transcription of ATP-Binding Cassette Transporter A1 Gene in a Liver X Receptor-Dependent Manner
- Fenofibric acid: In combination therapy in the treatment of mixed dyslipidemia (a review)
- Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography
- Stability indicating UPLC method for simultaneous determination of atorvastatin, fenofibrate and their degradation products in tablets
考研文獻
產品文件 (部分產品的分析圖譜無法提供,敬請諒解。)
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助,請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注:該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉,您搜索的分析圖譜無法提供。